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ABBREVIATIONS 
 
AA arachidonic acid  
ALA:    alpha-linolenic acid 
AUC:     area under the curve  
ApoB:    apolipoprotein B 
BMI:     body mass index 
CHD:     coronary heart disease 
CRP:     C-reactive protein 
CVD:     cardiovascular disease 
DHA:     docosahexaenoic acid 
EPA:     eicosapentaenoic acid 
FMD:     flow-mediated dilatation  
fRHI:     Framingham reactive hyperemia index  
HDL:     high-density lipoproteins 
HOMA-IR:    homeostasis model assessment estimate of insulin resistance 
iAUC:    incremental area under the curve 
ICAM-1:    intercellular adhesion molecule-1  
IDL:     intermediate-density lipoproteins 
LA:     linoleic acid 
LDL:    low-density lipoproteins 
MUFA:   monounsaturated fatty acids 
NO:    nitric oxide 
PAT:     peripheral arterial tonometry  
PREDIMED:    Prevención Dieta Mediterranea 
PUFA:    polyunsaturated fatty acids 
QUICKI:    quantitative insulin-sensitivity check index  
RHI:     reactive hyperemia index  
SEM:     standard error of the mean 
SFA:     saturated fatty acids 
VCAM-1:   vascular cell adhesion molecule-1  
VLDL:    very-low-density lipoproteins 
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1 INTRODUCTION 
 
1.1 Cardiovascular disease: epidemiology, pathophysiology, and risk factors  
 
Cardiovascular disease (CVD) is the leading cause of death worldwide. In 2008 alone,        
17.3 million people died of CVD, accounting for 31% of all major causes of deaths. Over the 
past two decades, disparate trends in CVD mortality have emerged in different regions of the 
world. While there has been a decline in CVD mortality in high-income countries as a result 
of improvement in treatment options and preventive strategies, a staggering increase has been 
observed in medium- and low-income countries. What was once considered a disease of the 
elderly is now also plaguing a much younger population, with an astonishing 42% of CVD 
deaths occurring under the age of 60 in developing countries. CVD continues to be a global 
public health and socioeconomic issue. In most cases, CVD can be prevented, but the rise in 
the disease incidence indicates that adequate preventive measures are still lacking (1, 2).  
 
The major pathological process underlying CVD is atherosclerosis, which is characterized by 
thickening and hardening of the arterial wall due to the formation of atheromatous plaques. 
The lesions develop slowly over the course of many years before any clinical symptoms 
become apparent. The disease process is complex and involves chronic inflammation and 
fibroproliferation commonly in the presence of high levels of plasma cholesterol (3). The 
initial step in the development of atherosclerosis is described by the widely accepted 
“response-to-injury” hypothesis, which postulates that the formation of atheromatous plaques 
is the result of some form of damage to the endothelium (4), a thin layer of endothelial cells 
covering the luminal surface of blood vessels. The endothelium acts as a selective 
permeability barrier and a metabolically active interface between the circulating blood and 
the arterial wall (5). It releases a number of vasoactive substances, prevents thrombosis, 
regulates vascular tone and growth, and modulates inflammatory responses (6). 
 
Different forms of physical and chemical insults, including hypertension, smoking, 
dyslipidemia, and hyperglycemia, can promote endothelial dysfunction (7). As a result, the 
endothelium decreases the production of vasodilators, most notably nitric oxide (NO), 
increases the release of vasoconstrictors, such as endothelin-1 (5), and enhances the 
expression of various endothelial adhesion molecules, such as vascular cell adhesion 
molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1). Consequently, 
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arteries experience prolonged constriction, and inflammatory cells bind to the endothelium 
via adhesion molecules, triggering a series of inflammatory processes (Figure 1) (7).  
 
Early visible manifestations of atherosclerosis are known as fatty streaks (Figure 2), which 
can be detected in early childhood. Fatty streaks are patchy deposits of cholesterol and 
cholesterol ester in the intimal layer of arteries (8). They are formed by an aggregation of 
lipid-laden macrophages, also known as foam cells. Fatty streaks differ from advanced 
atherosclerotic lesions in that the intimal architecture and the adjacent media remain largely 
unaffected. However, in more advanced stages, the formation of atheromatous plaques 
modifies the intima, the media, and even the adventitia, leading to the narrowing of arterial 
lumen (Figure 3) (9). 
 
Atheromatous plaques are formed by the gradual accumulation of foam cells in the 
subintimal layer of arteries. Both intra- and extracellular deposits of cholesterol and 
cholesterol ester make up the lipid core of the plaques. Various cells release inflammatory 
mediators that increase the adhesion of inflammatory cells, and lesions continue to grow as 
smooth muscle cells migrate to and proliferate in the intima and produce abundant 
extracellular matrix, forming the fibrous cap that provides stability to the plaques. 
Atherosclerosis remains clinically indolent until plaques significantly obstruct the arterial 
lumen, or until the fibrous cap weakens, causing plaques to rupture (Figure 4). Plaque 
rupture represents the most dangerous stage in the development of atherosclerosis. As the 
underlying lipid core is exposed to the blood, various procoagulant mediators are released 
and promote thrombus formation (4), which can lead to fatal heart attack or ischemic     
stroke (7). 
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Figure 1. Endothelial dysfunction: increased endothelial permeability;  
upregulation of endothelial adhesion molecules; leukocyte adhesion and  
migration into the subintimal layer. (Source: Ross, R) (4) 
 
 
 
 
Figure 2. Fatty streak formation: aggregation of foam cells; smooth muscle  
cell migration. (Source: Ross, R) (4)  
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Figure 3. Advanced atherosclerotic lesions: fibrous cap and necrotic core  
(apoptosis, necrosis, and lipid accumulation). (Source: Ross, R) (4) 
 
 
 
 
 Figure 4. Unstable atheromatous plaques: thinning of the fibrous cap and  
 plaque rupture. (Source: Ross, R) (4) 
  
6 
 
Major risk factors of the atherosclerotic disease include positive family history, smoking, 
obesity, diabetes, hypertension, and dyslipidemia (10). The clustering of central obesity, 
impaired fasting glucose, hypertension, and dyslipidemia has been termed the metabolic 
syndrome, which is defined as a constellation of three or more of the conditions listed in  
Table 1 (11).  
 
Table 1. Components of the metabolic syndrome.  
 
Risk Factor Defining Level 
Abdominal Obesity 
     Men 
     Women 
Waist Circumference 
>102 cm 
>88cm 
Triglycerides ≥150 mg/dL 
HDL cholesterol 
     Men 
     Women 
 
<40 mg/dL 
<50 mg/dL 
Blood pressure ≥130/85 mmHg 
Fasting glucose ≥110 mg/dL 
(Source: National Cholesterol Education Program) (11) 
 
Among the common risk factors, dyslipidemia is an extensively studied and well-established 
independent risk factor of CVD. It is a condition in which plasma levels of lipids and 
lipoproteins are abnormal. Considering the central role lipids play in the pathogenesis of  
atherosclerosis, dyslipidemia is a crucial treatment target in the management of CVD (11).  
 
Due to the hydrophobic nature of lipids, they are carried by specific transport vehicles known 
as lipoproteins in the circulatory system. There are several classes of lipoproteins, which 
differ from one another in their triglyceride and cholesterol content, protein components, and 
metabolic pathways. Major transporters of triglycerides are very-low-density lipoproteins 
(VLDL) and chylomicrons. While VLDL are synthesized in the liver, chylomicrons are 
derived from the intestine after fatty meals and carry postprandial triglycerides via the 
lymphatic system to the blood. The triglycerides carried by chylomicrons are released by the 
action of lipoprotein lipase, an enzyme present on the surface of the endothelium. This leads 
to the formation of chylomicron-remnant particles, which are smaller in size but still 
triglyceride-rich. The remnant particles are cleared from the circulation by binding to specific 
receptors in the liver. VLDL also undergo a series of delipidation, which results in the 
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formation of intermediate-density lipoproteins (IDL) and ultimately low-density lipoproteins 
(LDL) (12).  
 
LDL are major plasma transporters of cholesterol and cholesterol ester. Normally LDL are 
removed from the bloodstream by binding to LDL receptors, which are located in the liver 
and extrahepatic tissues. LDL not removed by LDL-receptors can bind to scavenger receptors 
on macrophages and induce the formation of foam cells (13). 
 
High-density lipoproteins (HDL) are another major group of lipoproteins synthesized in the 
intestine and the liver. A key function of HDL is reverse cholesterol transport, which 
describes the transport of cholesterol from peripheral tissues back to the liver (14). 
Epidemiological studies have consistently demonstrated an inverse relationship between 
HDL-cholesterol levels and CVD. Reducing the cholesterol load in peripheral cells is one of 
many potential cardioprotective effects of HDL. HDL may also show antioxidative, anti-
inflammatory, and endothelium-dependent vasodilatory effects (15). 
 
While high levels of HDL may reduce the risk of CVD, an increase in all other lipoproteins 
(VLDL, IDL, LDL, triglyceride-rich remnants, and lipoprotein(a)), which are collectively 
known as non-HDL, is considered proatherogenic. A common feature of all non-HDL 
particles is that each carries an apolipoprotein B (apoB) (16). There are two different apoB 
molecules: apoB-100 and apoB-48. ApoB-100 is synthesized in the liver and is present on all 
non-HDL particles except for chylomicrons, which carry apoB-48 synthesized exclusively in 
the intestine. ApoB-100 mediates the binding of non-HDL to LDL receptors for clearance 
from the bloodstream (17). Among the circulating non-HDL, LDL have the strongest link to 
atherosclerosis. Their atherogenic properties have been confirmed by studies examining 
individuals with genetic disorders causing very high levels of LDL (familial 
hypercholesterolemia). It has been shown that lowering LDL levels does not only prevent the 
formation of atherosclerotic plaques but also confer more stability to existing plaques (11). 
 
It was long believed that triglycerides are not directly implicated in the development of 
atherosclerotic lesions; however, triglyceride-rich lipoproteins, which also carry apoB, may 
induce the development of atherosclerotic lesions similar to LDL. Moreover, humans spend 
most of the day in a non-fasting state; non-fasting triglycerides act as a surrogate marker for 
non-fasting remnant cholesterol (18). Varbo et al. examined the causal relationship between 
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increased remnant cholesterol levels and risk for coronary heart disease (CHD) using data 
from three large Danish studies. The analysis showed that for every 1 mmol/L increase in 
non-fasting remnant cholesterol, the risk of ischemic heart disease was increased by 2.8 fold, 
independent of HDL reduction (19). Two epidemiological studies have shown that low levels 
of non-fasting triglycerides as a result of genetic mutations are associated with a decreased 
risk of CHD (20, 21). 
  
Lipid abnormalities do not commonly appear as isolated metabolic disturbances but are 
frequently accompanied by other CVD risk factors such as obesity and diabetes. Obesity is a 
prevalent health issue that has reached epidemic proportion. The Framingham Heart Study 
was among the first epidemiological studies showing a causal relationship between obesity 
and CVD (22); however, the underlying mechanisms, which involve diverse cellular 
pathways, are complex and only partially understood. Obesity is closely associated with the 
other risk factors of the metabolic syndrome. In fact, it has been regarded as the predominant 
risk factor in the development of the metabolic syndrome (11). The association between 
obesity and type-2 diabetes has been extensively studied. The risk of developing type-2 
diabetes is positively associated with body mass index (BMI). The disease risk increases 
exponentially at BMI > 25 mg/m
2
 (23, 24). Type-2 diabetes is in itself an independent risk 
factor of CVD (25).  
 
The link between obesity and CVD appears to relate to the secretory function of adipose 
tissue. Adipose tissue cannot simply be regarded as an inert storage of triglycerides; it is also 
a secretory organ. In addition to releasing free fatty acids, adipocytes synthesize and secrete 
numerous proteins that function as enzymes, cytokines, growth factors, and hormones. 
Collectively, these protein factors are known as adipokines, which participate in the 
regulation of diverse metabolic processes and the overall energy balance (26). A number of 
adipokines and their key metabolic functions are listed in Table 2 (27). 
 
Many adipokines exhibit proinflammatory properties and antagonistic functions in the insulin 
signaling pathways, inducing endothelial dysfunction and insulin resistance. Adiponectin is 
an adipokine with anti-inflammatory effects and is inversely related to insulin resistance and 
C-reactive protein (CRP) level. While the level of most adipokines increases in the presence 
of excess adipose tissue, the production of adiponectin has been shown to decrease in the 
obese state (26). This imbalance between the secretion of pro-inflammatory and anti-
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inflammatory adipokines in obesity contributes to a chronic, low-grade inflammatory state, 
which causes disturbances in metabolic homeostasis and triggers CVD. This is not only 
observed in visceral adipose tissue but also in perivascular adipose tissue, which is an 
emerging novel factor that modulates vascular function. The upregulation of pro-
inflammatory adipokines and the downregulation of anti-inflammatory adipokines in 
perivascular adipose tissue have been shown to promote the migration and activation of 
inflammatory cells and the migration and proliferation of vascular smooth muscle cells across 
the endothelium (28). 
 
Table 2. Adipokines and their metabolic functions.  
 
Adipokines Metabolic Functions 
Adiponectin  Suppression of hepatic gluconeogenesis 
Stimulation of fatty acid oxidation in liver and skeletal muscle 
Stimulation of glucose uptake in skeletal muscle 
Stimulation of insulin secretion  
Modulation of food intake and energy expenditure 
 
Leptin  Repression of food intake 
Promotion of energy expenditure 
Stimulation of fatty acid oxidation in liver, pancreas, and 
skeletal muscle 
Modulation of hepatic gluconeogenesis 
Modulation of pancreatic β-cell function 
 
Chemerin  Enhancement of insulin-stimulated glucose uptake and insulin 
receptor substrate-1 phosphorylation in 3T3-L1 adipocytes 
 
Visfatin  Stimulation of insulin secretion in mice 
Uncertain effect on insulin resistance in rodents and humans 
 
Vaspin  Improvement of insulin sensitivity in mice 
Uncertain effect on insulin sensitivity in humans 
(Source: modified Rabe, K) (27) 
 
Inflammation plays a key role in the formation of atherosclerotic lesions. Chronic 
inflammation is closely associated with the development and progression of CVD. CRP is an 
acute phase reactant that is mainly produced by hepatocytes in response to the production of 
proinflammatory cytokines. CRP forms a complex with atherogenic oxidized LDL and can be 
found within atheromatous plaques. Although CRP is a nonspecific marker of inflammation, 
it has been regarded as a novel biomarker of CVD. However, due to the inconclusive data, its 
clinical utility in the risk stratification of CVD still remains unclear (29).  
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Excluding genetic factors, most of the above-mentioned CVD risk factors are modifiable 
through lifestyle intervention. Dietary modification is an indispensable part of CVD 
prevention and management. The amount and the types of food eaten have great influence on 
a person’s health. In the last half-century, there has been a growing interest in identifying 
healthy dietary patterns and finding so-called “functional foods”. The Western-type diet is 
commonly regarded as unhealthy due to the high intake of red and processed meats, refined 
grains, and sugary foods and beverages. This dietary pattern has been associated with 
increased risk of obesity, type-2 diabetes, CVD, and certain types of cancer (30, 31). In 
contrast, a traditional Mediterranean diet is widely recognized as a healthy dietary pattern. It 
is characterized by large amounts of vegetables, fruit, legumes, nuts, and olive oil, as well as 
moderate consumption of fish, poultry, dairy products, and wine, with low consumption of 
red meat (32). Close adherence to a Mediterranean diet is linked to reduced CVD incidence 
and mortality (33). This finding has prompted many studies to closely examine specific 
components of the Mediterranean diet. Among the most studied dietary components are nuts. 
In the past two decades, ample studies have explored the potential health benefits of nut 
consumption (34, 35). Walnuts are among the most studied tree nuts because of their high 
nutritional value and unique composition.  
 
1.2 Walnuts: historical relevance, nutritional value, and health benefits 
 
Walnuts are among the oldest tree nuts known to mankind. Records of their existence date 
back as far as 7000 BC (36). Walnuts belong to the genus Juglans of the botanical family 
Juglandaceae. Of all walnut species, Juglans regia is the most cultivated (37).  
The ancient Greeks were the pioneers of walnut cultivation. They did not only regard walnuts 
as a source of nutrients but also used them as medicine and dyes. In ancient times, walnuts 
were thought to have many healing properties. Some believed that walnuts had astringent and 
stomachic effects and could stimulate appetite and improve digestion. Even walnut husk and 
bark could be used to treat inflammation, pain, and bowel ailments. Also, walnut milk was a 
nutritious alternative to dairy products (36). Perhaps the historical importance of walnuts is 
best described by the meaning of their scientific name: “Juglans” is the Latin term for “nut of 
Jupiter” and “regia” means “royal”. In Greek mythology, Jupiter is the king of the gods. The 
name reflects the ancient belief that walnuts were “the choice of the gods” (38). Casas-
Agustench et al. mentioned an old tale: “in ancient days when men lived upon acorns, the 
gods lived upon walnuts” (36). 
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In modern times, the potential health benefits of walnuts have not been overlooked either. For 
decades, scientists have been trying to determine the favourable effects of walnut 
consumption and identify the components of walnuts that elicit these effects. Walnuts are 
considered energy-dense food and provide approximately 654 kcal/100g serving (39); 
however, the actual metabolizable energy content of walnuts is lower than the estimated 
energy content (40). Although the main constituent of walnuts is fat, the fatty acid 
composition is considered healthy, because unsaturated fatty acids predominantly constitute 
the total fat content, whereas the amount of saturated fatty acids (SFA) is low. Walnuts have 
a unique fatty acid distribution that distinguishes them from other nuts. While most nuts are 
high in monounsaturated fatty acids (MUFA), walnuts are primarily composed of 
polyunsaturated fatty acids (PUFA: 47% of total weight), mainly linoleic acid (LA) and 
alpha-linolenic acid (ALA) (39). Of all edible plants, walnuts may have the highest content of 
ALA (9%), and compared with other nuts, they are the only nuts with a significant amount 
ALA (Figure 5) (41).  
 
There is evidence showing an inverse relationship between ALA intake and death from CHD. 
Pan et al concluded in a meta-analysis that each increment of 1 g/d intake of ALA was 
associated with a 10% risk reduction for CHD death (42). Contrary to existing data showing a 
consistent inverse relationship between ALA intake and CVD, Marklund et al. observed in a 
prospective cohort study involving 60-year-old Swedish men and women without prior CVD 
that plasma ALA level determined at baseline was linked to moderately elevated CVD risk in 
women. The authors discussed that this finding does not conclude that ALA intake raises 
CVD for several reasons: Serum ALA in cholesterol esters may not be a strong biomarker of 
dietary consumption when compared with other PUFA in part due to its extensive 
metabolism via β-oxidation and conversion to long-chain PUFA. Also, the results may be 
confounded by the high amount of trans-fat or saturated fat found in margarine and spreads 
that were sources of ALA (43).   
 
ALA is a plant-based essential omega-3 fatty acid that has also been shown to elicit anti-
inflammatory and anti-atherogenic effects (44, 45). It is also the precursor of endogenous 
synthesis of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). EPA and DHA 
are long-chain n-3 PUFA that are typically found in oily fish. Intake of long-chain n-3 PUFA 
has been associated with a decrease in triglyceride levels (46). Meta-analyses of randomized 
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control trials have shown that EPA and DHA may have antihypertensive effects (47) and may 
improve endothelial function (48). Moreover, an inverse relationship between serum EPA 
and DHA intake and all-cause mortality was observed in senior Swedish men and women 
(43).
 
Figure 5. Alpha-linolenic acid content in 100 g nuts. (Data from source: Robbins KS) (41) 
 
Like all plants, walnuts are cholesterol-free. However, they contain compounds that are 
structurally similar to cholesterol known as phytosterols. Phytosterols are non-nutritive, and 
their intestinal absorption is poor (35). Yet there is evidence indicating that phytosterols may 
inhibit the cholesterol uptake in the intestine (49). 
 
In addition to the favourable lipid profile, walnuts also contain many other potentially 
cardioprotective nutrients. The major nutrients in walnuts are listed in Table 3 (39). Walnuts 
are a good source of plant protein and dietary fiber (35). They contain relatively high 
quantities of L-arginine, an amino acid that acts as the precursor for the biosynthesis of NO 
(50). A number of vitamins needed for proper cellular function are also found in walnuts. For 
example, folate, also known as vitamin B9, is essential for various metabolic functions. 
Humans need to obtain the required amounts of folate through diet because de novo synthesis 
is not possible. Folate plays a vital role in DNA synthesis and repair (51). Moreover, it 
controls the plasma homocysteine levels, an amino acid produced in the metabolism of 
methionine and linked to increased cardiovascular risk (52). 
 
Walnuts also contain sizable amounts of γ-tocopherol, which is a form of vitamin E that 
exhibits antioxidant activities and inhibits the proliferation of smooth muscle cells, an 
important process in the development of atherosclerosis. Furthermore, γ-tocopherol elicits 
anti-inflammatory effects by inhibiting the activity of cyclooxygenase-2. Although               
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γ-tocopherol may be much less studied than α-tocopherol, some evidence suggests an inverse 
relationship between γ-tocopherol concentration and CVD (53). 
 
Table 3. Major nutrients in 100 g of walnuts.  
 
Nutrients Amount 
Energy (kcal) 654
a
 
Carbohydrate (g) 14 
Protein (g) 15 
   Arginine (g) 2.3 
Lipid (g) 65 
   Saturated fatty acids (g) 6 
   Monounsaturated (g) 9 
   Polyunsaturated (g) 47 
Minerals  
   Na (mg) 2 
   K   (mg) 441 
   Ca (mg) 98 
   Mg (mg) 158 
   Fe (mg) 2.91 
   Se (µg) 4.9 
Vitamins  
   α-tocopherol (mg) 0.7 
   γ-tocopherol (mg) 20.83 
   Folate (µg) 98 
Phytosterols (mg) 92 
Dietary fiber (g) 6.7 
 
(Source: US Department of Agriculture National Nutrient Database for  
Standard Reference, Release 24) (39); 
a 
newer data indicate that metabolizable  
energy may be lower (40). 
 
Walnuts are also rich in polyphenols, which are antioxidants with the ability to scavenge free 
radicals and regulate metal-chelating reactions. Studies have shown that polyphenols may 
protect LDL from oxidative modifications (54) and prevent endothelial dysfunction by 
modulating NO and endothelin-1 synthesis (55), reducing the risk of atherosclerosis. 
Interestingly, polyphenols can also increase the antioxidant activities of other compounds 
such as vitamin C, vitamin E, and β-sitosterol. Compared with other tree nuts and peanuts, 
walnuts have the highest amount of polyphenols (56).  
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In addition, the composition of minerals in walnuts is also considered beneficial. Walnuts 
have a low sodium content (35). Excess sodium intake is associated with high blood pressure 
and a number of other adverse health conditions. Approximately 75% of the daily salt 
consumption is obtained from processed foods. Intake of foods with high sodium content can 
displace foods containing other valuable minerals such as calcium, potassium, and 
magnesium (57). In walnuts, the relation of sodium to the other minerals (calcium, potassium, 
and magnesium) is considered favourable (35). 
 
Walnuts with their complex mixture of macronutrients and micronutrients have been shown 
to have beneficial effects on many aspects of health. In animal models, walnuts have been 
demonstrated to improve cognitive functions (58, 59) and reduce the risk of certain types of 
cancer (60, 61). The potential cardioprotective effects of walnuts have been most extensively 
researched in humans.  
 
Epidemiological studies have consistently shown an inverse relationship and dose-dependent 
effects with respect to nut consumption and risk of CVD. A pooled analysis of four large 
cohort studies (Adventist Health Study, Iowa Women’s Health Study, Nurses’ Health Study, 
and Physicians’ Health Study) conducted in the U.S. demonstrated that subjects with the 
highest nut consumption had a 37% reduction in the risk of CHD mortality. Furthermore, the 
study showed that the risk of CHD mortality decreased by 8.3% for each weekly serving of 
nuts (approximately 30 g) (62).  
 
The Prevención Dieta Mediterranea (PREDIMED) study is a landmark primary prevention 
trial that examined the cardioprotective effects of a Mediterranean diet supplemented either 
with nuts (30g mixed nuts/d, 50% walnuts) or olive oil. This multicenter study conducted in 
Spain included 7447 subjects between the age of 50 and 88 years who were at high risk of 
developing CVD but did not have CVD at the start of the study. After a median follow-up of 
4.8 years, the Mediterranean diets supplemented with mixed nuts or olive oil decreased 
cardiovascular events by about 30%, and the nut-enriched diet decreased the risk of stroke by 
49% when compared with a low-fat control diet (63). In an earlier randomized, controlled, 
secondary prevention trial, the Lyon Heart Study, a Mediterranean diet rich in ALA, which is 
present in a significant amount in walnuts, was shown to significantly reduce recurrent 
coronary events in subjects with a first myocardial infarction (64). 
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Perhaps the most widely studied CVD risk factors are plasma lipids and lipoprotein levels 
(56). One of the first clinical studies that investigated the effects of walnuts on plasma 
lipoprotein levels was published by Sabaté et al in 1993. Eighteen healthy men between the 
age of 18 and 43 years followed two experimental diets for a total of eight weeks. Both diets 
had the same composition except that one diet replaced some foods with walnuts (20% of 
total calorie intake). Results showed that the walnut diet reduced total cholesterol by 12% and 
LDL-cholesterol by 16%. Although HDL-cholesterol also decreased, the total cholesterol to 
HDL-cholesterol ratio decreased as well (65). Subsequent clinical studies have consistently 
shown that walnuts can lower LDL-cholesterol levels by 9-16% in a dose-dependent manner.  
Beyond the improvement of plasma lipoprotein levels, short-term feeding trials have also 
demonstrated that frequent walnut consumption improves other traditional CVD risk factors 
such as insulin resistance and hypertension as well as novel risk factors such as oxidative 
stress, inflammation, and vascular reactivity (56). 
 
1.3 Aims of the study 
 
The majority of previous feeding trials with walnuts were conducted in subjects at increased 
risk of developing CVD (risk factors such as metabolic syndrome, type-2 diabetes, and 
hypercholesterolemia) (66). A few studies involving healthy individuals were selected from a 
younger age group (< 50 years) (65, 67-69), and in some cases, there was an 
underrepresentation of women (65, 69). It is important to note that the metabolism of 
premenopausal women differs from that of postmenopausal women. There is evidence 
showing a sudden rise in CVD incidence after menopause. Thus, premenopausal women may 
have a different risk profile than postmenopausal women (70). In addition, many studies 
focused primarily on the effect of walnuts on fasting lipid and glucose metabolism. There is a 
scarcity of evidence concerning postprandial metabolism (66). Therefore, this study aimed to 
examine whether the favourable changes in fasting lipid and glucose metabolism observed in 
previous studies would also apply to healthy Caucasian men and women of a higher age 
group (≥ 50 years). Furthermore, the present study also aimed to analyze the effect of walnut 
consumption on postprandial lipid and glucose metabolism, circulating levels of adipokines 
and CRP, as well as endothelial function, body weight, and blood pressure. 
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2 MATERIALS AND METHODS   
 
2.1 Study subjects 
 
The study protocol was approved by the Ethics Committee of the Medical Faculty of 
Ludwig-Maximilians-University of Munich and was registered on https://clinicaltrials.gov 
(NCT01188902). 
A total of 96 healthy men and healthy postmenopausal women aged 50 and above were 
interviewed and examined. All subjects were recruited through posters on hospital bulletin 
boards and in pharmacies, or via an article in a local newspaper and the hospital magazine 
“LMU Klinikum Aktuell”. The screening evaluation involved obtaining subjects’ medical 
history, a physical examination, and a fasting blood test. Inclusion criteria (Table 4) and 
exclusion criteria (Table 5) were used to determine the eligibility of each subject. Fifty-seven 
eligible men and women were recruited in the study.   
 
Table 4. Inclusion criteria.  
 
Inclusion Criteria 
 
 healthy Caucasian men and healthy Caucasian postmenopausal women 
 age ≥50 
 written informed consent prior to study participation 
 
 
Table 5. Exclusion criteria.  
 
Exclusion Criteria 
 
 Evidence of alcohol (women >70 g/week, men >140 g/week), tobacco or drug abuse 
 Obesity ≥35 kg/m2 
 Diabetes mellitus 
 Hypertension >140/90 mmHg or history of hypertension 
 LDL- cholesterol >190 mg/dL, Triglycerides >350 mg/dL 
 History of atherosclerotic disease 
 Liver disease of any etiology  
 Kidney disease of any etiology (GFR ≤50 ml/min/1.73) 
 Uncontrolled thyroid disease or other endocrine diseases 
 Acute or chronic inflammatory diseases 
 Active malignancy 
 Current or previous (within 3 months) treatment with antidiabetic drugs, 
hypolipidemic drugs, antihypertensive drugs, anti-inflammatory drugs, vitamin E, 
hormonal replacement therapy 
 Known allergy to nuts and milk proteins; lactose intolerance 
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2.2 Study design 
 
The study employed a randomized, controlled, prospective, cross-over design (Figure 6). 
Each subject followed a nut-free, Western-type diet during a two-week run-in period. 
Thereafter, subjects were randomized to two different diet phases, each lasting for eight 
weeks and separated by a two-week wash-out period. A group of 28 subjects first followed a 
diet with walnuts and then switched to a control diet. Another group of 29 subjects followed 
the two diets in reverse order. 
 
 
 
Figure 6. Study design.  
 
2.2.1 Visit 0 
Potential study subjects were interviewed in the outpatient clinic Medizinische Poliklinik II in 
Klinikum Großhadern. After obtaining subject’s medical history, a physical examination was 
performed. Each subject received detailed information regarding the procedures of the study 
and the possible risks involved: bruise and slight pain at the site of venipuncture, temporary 
paresthesia in the arm after the assessment of endothelial function, and first manifestation of 
nut allergy. After obtaining informed consent, fasting blood samples were drawn to determine 
blood count and parameters of fasting lipid and glucose metabolism, liver, kidney, and 
thyroid function as well as CRP. Test subjects were contacted by phone to inform them of 
their eligibility. They were instructed to keep a three-day diet protocol and submit it prior to 
the next visit. The purpose of this protocol was to assess each subject’s dietary habits and to 
allow subjects to familiarize themselves with the process of completing a diet protocol.  
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2.2.2 Visit 1 
Test subjects attended a consultation session with a nutritionist, who evaluated each subject’s 
dietary habits using the three-day diet protocol completed prior to visit 1. Strict calorie 
restrictions were not suggested due to the differences in the individual daily energy output, 
which largely depends on age, gender, BMI, and the level of physical activity. However, 
adherence to a balanced Western-type diet consisting of 35 % fat (15 % SFA), 15 % protein 
and 50 % carbohydrate was requested. Subjects were instructed to complete a four-day diet 
protocol and submit it prior to each of the subsequent visits. 
 
2.2.3 Visit 2, 3, 4, 5 
Subjects arrived at the site after fasting for at least eight hours. Upon arrival, a brief medical 
history was obtained. Thereafter, subjects underwent a series of tests consisting of a physical 
examination, a mixed meal test and a noninvasive assessment of the endothelial function. An 
indwelling venous cannula was inserted to draw fasting blood samples (at 0 minute) and 
postprandial blood samples at 15, 30, 60, 120, 180, 240, 360, and 480 minutes after drinking 
the test drink. The analyzed parameters are shown in Table 6. A noninvasive assessment of 
the endothelial function using EndoPat 2000 was performed 240 min postprandially at noon 
to avoid potential confounding by the early morning blunting in endothelial function as 
reported previously (71). Subjects met with the nutritionist again on each visit. Dietary 
adherence was assessed using a four-day diet protocol. 
 
Table 6. Analyzed blood parameters.  
 
apoB: apolipoprotein B; HDL-C: high-density lipoprotein cholesterol; HOMA-IR: homeostasis model 
assessment estimate of insulin resistance; LDL-C: low-density lipoprotein cholesterol; QUICKI: quantitative 
insulin-sensitivity check index; VLDL: very-low-density lipoprotein cholesterol.   
 
 
Fasting blood parameters Postprandial blood parameters 
 
 lipid metabolism: total cholesterol, 
total triglycerides, LDL-C, HDL-C, 
VLDL-C, VLDL-triglycerides, 
free fatty acids, apoB 
 glucose metabolism: glucose, HbA1c, 
insulin, QUICKI, HOMA-IR 
 
 
 lipid metabolism (at 60 120, 240, 360, 
480 min): total cholesterol, 
total triglycerides, LDL-C, HDL-C, 
VLDL-C, VLDL-triglycerides, 
Chylomicron-triglycerides,  
 glucose metabolism: (at 15, 30, 60, 120, 
180 and 240 min.), glucose, insulin 
19 
 
2.2.4 Dietary consultation 
The nutritionist contacted subjects by phone in week 4, 6, 14 and 16 to inquire about their 
current health and medication status, possible problems involved with dietary adherence and 
the completion of diet protocols. Dietary compliance was assessed using the four-day diet 
protocol.  
 
2.3 Nutrition 
 
2.3.1 Diets 
Subjects were asked to follow a Western-type diet (35 % fat, of which 15 % saturated fatty 
acids, 15 % protein, and 50 % carbohydrate) throughout the study. They were also requested 
to discontinue the consumption of products containing nuts, the use of fish oil and Vitamin E 
supplements, and to maintain their body weight within 2 kg of their baseline value. In the 
walnut phase, subjects were provided with a daily allowance of 43 g of shelled, prepackaged 
walnuts, the amount of which contained about 30 g of fat. Subjects were instructed to replace 
30 g of saturated fat with the walnuts. Subjects were provided with handouts to assist them 
with the integration of walnuts into their diets. In the control phase, subjects were requested 
to continue the Western-type nut-free diet. Dietary adherence was closely monitored using a 
four-day (on three weekdays and one weekend day) diet protocols.  
 
2.3.2 Mixed meal test 
Two different test drinks (A and B) were provided to the test subjects. Fourteen subjects 
received test drink A, which contained 25 g olive oil and 200 ml Fresubin® original drink 
(Fresenius Kabi: 200 kcal, 15 % protein, 55 % carbohydrate, and 30 % fat). The drink had a 
total of 427 kcal which consisted of 67 % fat (absolute amount 32 g), 7 % protein, and 26 % 
carbohydrate. Thirty-two subjects received test drink B which consisted of 90 g Calshake® 
powder (Fresenius Kabi), 120 ml 30 % cream, 120 ml 3.5 % milk and 25 g corn oil. The 
drink had a total of 1104 kcal and consisted of 72 % fat (absolute amount 88 g), 4 % protein 
and 24 % carbohydrate.  
 
2.4 Endothelial function 
 
In this study, the endothelial function was assessed using a non-invasive peripheral arterial 
tonometry (PAT) device (EndoPat). EndoPat is a device that uses plethysmographic 
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bio-sensors to measure the arterial pulsatile volume changes (PAT Signal) in the distal two-
thirds of the fingers. The bio-sensors measure changes in peripheral arterial tone elicited by a 
five-minute occlusion of the brachial artery in one arm using a standard blood pressure cuff. 
Reactive hyperemia is induced by the release of the pressure cuff. During this period of time, 
an endothelium-dependent flow-mediated dilatation (FMD) in the finger arteries is captured 
by the bio-sensors as an increase in the PAT Signal amplitude. The contra-lateral arm serves 
as a control to assess the non-endothelial mediated changes in vascular tone (72). 
 
The examination took place 240 min after the mixed meal test in a quiet, thermoneutral room 
(20-25 °C). Subjects were asked to remove watches, rings, jewelry, and restrictive clothing 
that could impede blood circulation in the arms. If necessary, fingernails were trimmed to 
avoid damaging the internal membrane of the bio-sensors. Prior to the study, subjects were 
allowed to rest in a bed for at least 15 minutes to attain a relaxed cardiovascular steady-state 
and acclimatize to room temperature. The occlusion cuff was placed around the upper arm 
without the indwelling needle, and the same arm was used on all visits. The bio-sensors were 
placed on the same finger in both hands, either on the index or middle finger. During the     
15-minute test, subjects were asked to refrain from speaking and moving. The baseline PAT 
signal was measured for 5 min. Thereafter, a pressure cuff on the test arm was inflated to  
200 mmHg, or at least 60 mmHg above the systolic blood pressure, to occlude the brachial 
artery. The cuff was deflated after 5 min. The bio-sensors measured changes in PAT signal 
for a further 5 min. The reactive hyperemia index (RHI) (Figure 7) and the Framingham RHI 
(fRHI) were determined using methods previously described (73).  
 
 
Figure 7. Reactive hyperemia index (RHI) calculation.  
A: Mean PAT amplitude between 90s-150s post occlusion of the test arm. B: Mean PAT amplitude from the 
baseline period of the test arm. C: Mean PAT amplitude between 90s-150s post occlusion of the control arm. D: 
Mean PAT amplitude from the baseline period of the control arm. (Source: http://www.itamar-
medical.com/EndoPAT™/FAQ) (74). PAT: peripheral arterial tonometry. 
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2.5 Laboratory analysis of blood samples 
 
2.5.1 Lipid parameters 
EDTA-coagulated blood samples were used to analyze lipid parameters. Plasma was obtained 
by centrifugation at 3.000 rpm for 10 minutes. Cholesterol and triglycerides in plasma as well 
as in lipoproteins were determined using enzymatic colorimetric methods at 37°C on an 
Alcyon 300 analyzer with reagents obtained from Diagnostic System. Total cholesterol and 
total triglycerides were quantified by placing plasma directly in Alcyon 300 analyzer.  
 
Cholesterol 
Cholesterol was quantitatively analyzed using the CHOD-PAP-method. First, cholesterol 
esterase catalyzed the hydrolysis of cholesterol esters to cholesterol and free fatty acids. 
Free cholesterol was then oxidized by cholesterol oxidase to cholest-4-en-3-one and 
hydrogen peroxide. The formed hydrogen peroxide oxidatively coupled with phenol and 
4-aminoantipyrine in the presence of peroxidase to yield a red coloured quinoneimine 
dye (Trinder reaction), which was measured spectrophotometrically at 500 nm. 
 
Triglycerides 
Triglycerides were quantitatively analyzed using lipoprotein lipase to hydrolyze 
triglyceride to glycerol and then followed by the quantification of glycerol. In the 
presence of ATP, glycerol was catalyzed to glycerol-3-phosphate and ADP. 
Glycerol-3-phosphate was then oxidized by glycerol-3-phosphate oxidase to 
dihydroxyacetone phosphate and H2O2.  The quinoneimine dye was also formed in the 
Trinder reaction (see analysis of total cholesterol).  
 
Chylomicrons, VLDL, HDL, LDL, non-HDL, and apoB 
The individual lipoproteins (HDL, LDL, VLDL and chylomicrons) were first isolated by 
ultracentrifugation using a Beckman L-60 centrifuge in a type 50.4 Ti rotor. First, 
chylomicrons were isolated by adding 3 ml of plasma and 3.5 ml of NaCl solution at a 
density of 1.006 g/ml to a Beckman centrifuge tube, which was then centrifuged at 5ºC at 
20.000 rpm for 20 min. The chylomicron fraction, a thin layer floating on the top of the 
gradient, was collected. The rest of the plasma was then placed in a new centrifuge tube 
and 3 ml of the same NaCl solution was added. The tubes were centrifuged at 5ºC at 
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50.000 rpm for 18 hours. The top fraction contained VLDL while the bottom fraction 
contained HDL and LDL. 
The subnatant obtained from the ultracentrifugation was used to quantify                  
HDL-cholesterol. First, 20 μl heparin and 30 μl manganese (II) chloride (MnCl2) were 
added to 500 μl subnatant in a centrifuge tube. The mixture was placed in a refrigerator 
for 30 min and then centrifuged at 5ºC at 12.000 rpm for 15 min. Subsequently, the 
supernatant was collected and placed in the Alcyon 300 analyzer to determine the 
cholesterol content. LDL cholesterol was calculated by subtracting HDL cholesterol 
from the total cholesterol in the infranatant of the VLDL-spin. Non-HDL-cholesterol was 
calculated using the equation: non-HDL-cholesterol = total cholesterol (mg/dl) -      
HDL-cholesterol (mg/dl). ApoB was determined by immunoturbidimetric methods using 
a commercially available reagent kit (DiaSys Diagnostic Systems, Holzheim, Germany).  
 
2.5.2 Plasma fatty acids  
Dietary compliance was analyzed using the diet protocols, which were evaluated with Prodi 
software version 5.8. A maximum of 20 % deviation from the dietary guidelines mentioned in 
section 2.3.1 was tolerated. The composition of fatty acids in plasma was used as a biological 
marker for dietary compliance and was determined by the research team of Prof. Dr. Berthold 
Koletzko at Dr. von Hauner Children’s Hospital in Munich using methods previously 
described. In brief, 100 µl of plasma, 100 µl of an internal standard (1,2-dipentadecanoyl-sn-
glycero-3-phosphocholine dissolved in methanol) and 0.6 ml methanol were combined in 
glass tubes and shaken for 30 s. Samples were centrifuged at 900 g for 5 min. The methanolic 
supernatant was transferred into another glass tube. Twenty-five µl sodium methoxide 
solution was added to the supernatant and the tubes were shaken while selective synthesis of 
methyl esters from glycerophospholipid fatty acids proceeded at room temperature. The 
reaction was stopped after 3 min by adding 75 µl methanolic HCl. Fatty acid methyl esters 
were extracted by adding 300 µl hexane and shaking the tubes for 30 s. The extraction was 
repeated. Combined extracts were dried under nitrogen flow at room temperature and 
individual fatty acid methyl esters were quantified using gas chromatography (75). 
 
2.5.3 Other parameters 
Parameters of glucose metabolism (glucose, insulin, HbA1c, HOMA-IR and QUICKI) and 
CRP were analyzed in the Department of Clinical Chemistry in Klinikum Großhadern. 
Glucose was quantified using the hexokinase method performed with a multi-channel 
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analyzer (Beckman Coulter AU2700). Automated sandwich immunoassays based on the 
principle of electrochemiluminescence (Roche Diagnostics) were implemented on a 
Roche Cobas e411 immunoanalzyer for the quantification of insulin. HbA1c was determined 
using the automated HPLC (high-performance liquid chromatography) method performed on 
a Bio-Rad Variant II HPLC system. HOMA and QUICKI indices were calculated from 
fasting glucose and insulin values using the following formulas:  
HOMA = glucose (mg/dL) x insulin (μU/mL)/405, 
QUICKI = 1 / [log(insulin μU/mL) + log (glucose mg/dL)].  
 
The concentration of CRP was determined using a particle-enhanced immunoturbidimetric 
assay performed on a multi-channel analyzer (Beckman Coulter AU2700). Fasting 
concentration of adipokines, VCAM-1, ICAM-1, and endothelin-1 were determined using 
commercially available ELISA kits (adiponectin and leptin: Millipore, Billerica; chemerin, 
visfatin, and vaspin: BioVendor, Asheville; VCAM-1, ICAM-1 and endothelin-1: R&D 
Systems Europe, Abingdon, UK). 
 
2.6 Area under the curve (AUC) and incremental area under the curve (iAUC) 
 
Total area under the curve (AUC) and incremental area under the curve (iAUC) were used to 
analyze postprandial lipid and glucose metabolism. The trapezoidal rule was used to 
approximate the AUC (Figure 8). The iAUC was calculated by subtracting the baseline area 
from the total AUC. The baseline area is defined as the area under the fasting level. Two 
different calculations were used to determine the baseline area, depending on whether the 
fasting value was higher or lower than the postprandial value at 8h (Figure 9 and Figure 10).  
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Figure 8. Area under the curve (AUC).The trapezoidal rule: AUC 1 = (b-a) x (ya+ yb)/2,  
    Total AUC = AUC 1 + AUC 2 + ACU 3 + AUC 4 + AUC 5 
 
 
 
 
Figure 9. Incremental area under the curve (iAUC), if y0 ≤ y8:  
                iAUC = Total AUC – (y0 x 8) 
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Figure 10. Incremental area under the curve (iAUC), if y0 > y8:  
                  iAUC = Total AUC –8x (y0 + y8)/2 
 
2.7 Statistics  
 
The primary outcome measure was non-HDL-cholesterol. Secondary outcome measures 
included: fasting total cholesterol, triglycerides, VLDL-cholesterol, VLDL-triglycerides, 
LDL-cholesterol, HDL-cholesterol, apoB, glucose, insulin, HOMA-IR, QUICKI, HbA1c, 
adiponectin, leptin, visfatin, vaspin, chemerin, ICAM-1, VCAM-1, endothelin-1, CRP, and 
fatty acid profiles; postprandial glucose, triglycerides, chylomicron-triglycerides, VLDL-
triglycerides and endothelial function; blood pressure, BMI, waist circumference; dietary 
composition. An estimated sample size of 40 subjects would be required to ensure an overall 
power of 90% to detect a mean difference of 20 mg/dL in non-HDL-cholesterol for 
comparing walnut diet with control diet, assuming a drop-out rate of 33%. Power calculations 
were based on the data of Sabate et al. (65). The statistical analysis was conducted with the 
help of statistician Dr. Renee Stark (Helmholtz-Zentrum Munich). Results are reported as 
mean ± standard error of mean (SEM), unless otherwise stated. Dietary components were 
compared using two-tailed paired t-test or the Wilcoxon signed-rank test. Postprandial lipid 
and glucose measurements were evaluated using AUC and iAUC and a two-step process to 
assess changes in the shape of postprandial curves: first, pre-control vs. post-control and pre-
walnut vs. post-walnut curves were compared at each time point; second, a model assessing 
the interaction between treatment and time was used. A mixed model was used to adjust for 
gender, age, BMI, diet sequence, and repeated measures for all comparisons (except for 
dietary components). Statistical significance was set at p < 0.05. Subject randomization 
(using a complete block design) and statistical analysis were performed on SAS 9.2. 
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3 RESULTS 
 
3.1 Subject characteristics 
 
Of 96 screened subjects, 72 fulfilled all inclusion criteria (Figure 11). Fifteen subjects 
declined participation prior to randomization. Fifty-seven subjects were randomized. During 
the two-week run-in period, five subjects were excluded from the study due to illness. In the 
first diet phase, two subjects with control diet declined further participation after visit two 
due to personal reasons, and one subject with walnut diet was excluded in week eight due to 
uncontrollable eating attacks with excessive calorie intake recorded in the diet protocols. In 
the washout phase, one subject, after exiting the control phase, was excluded due to excessive 
alcohol consumption (> 20 g/d) recorded in four consecutive diet protocols, and another 
subject in the same diet group terminated the study due to illness. Another subject, after 
exiting the walnut diet phase, was also removed from the study due to persistent hypertension 
measured hourly on visit two and three. 
 
 
Figure 11. Flowchart of study subjects.  
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A total of 46 subjects (11 men and 35 women) completed all three phases of the study. Nine 
subjects had hypothyroidism that was controlled with L-thyroxine. Six subjects were 
withdrawn from data analysis due to adverse events listed in section 3.2. In the subsequent 
sections, the data only refer to the remaining 40 subjects (10 men, 30 women). The 
characteristics of the subjects obtained at screening are described in Table 7. 
 
Table 7. Demographic characteristics and baseline values of anthropometric measurements, fasting lipid and 
glucose parameters and CRP. 
 
Variables Baseline* 
Gender m = 10, w = 30 
Age (y)   60 ± 1 
BMI (kg/m
2
)   24.9 ± 0.6  
Waist circumference (cm)   86 ± 2 
Systolic blood pressure (mmHg) 119 ± 2 
Diastolic blood pressure (mmHg)   75 ± 2 
Total cholesterol (mg/dL) 220 ± 5 
VLDL-cholesterol (mg/dL)   16 ± 2 
LDL-cholesterol (mg/dL) 133 ± 5 
HDL-cholesterol (mg/dL)   71 ± 2 
non-HDL-cholesterol (mg/dL) 149 ± 5 
Total triglycerides (mg/dL)   88 ± 6 
VLDL-triglycerides (mg/dL)   54 ± 7 
Apolipoprotein B (mg/dL)   88.8 ± 2.4  
Glucose (mg/dL)
1
   92 ± 1 
Insulin (µU/mL)
1
     7.0 ± 0.6  
HOMA-IR
1
     1.7 ± 0.2 
QUICKI
1
     0.37 ± 0.01 
HbA1c (%)
1
     5.5 ± 0.1 
CRP (mg/dL) < 0.1 (< 0.1-1.3) 
*Baseline values obtained on the first study visit, prior to dietary intervention. Values are mean ± SEM or 
median (range), n = 40 for all parameters except those marked with 
1
 (n = 35). BMI: body mass index; VLDL: 
very-low-density lipoproteins; LDL: low-density lipoproteins; HDL: high-density lipoproteins; HOMA-IR: 
homeostasis model assessment estimate of insulin resistance; QUICKI: quantitative insulin-sensitivity check 
index; CRP: C-reactive protein.  
28 
 
3.2 Adverse events 
 
Twenty-three study subjects reported the adverse events listed in Table 8. Eight subjects had 
mild symptoms of common cold. The most frequently used medications were low-dose     
non-opioid analgesics (aspirin, ibuprofen, paracetamol, and diclofenac), which were taken no 
more than four times by each of the 13 subjects throughout the entire study and with at least 
four days between the last use of medication and the following study visit.  
 
Table 8. Adverse events. 
 
Adverse event Number of Subjects 
Common cold 8 
Tonsillitis  1 
Medication  
    Analgesics 13 
    Antibiotics 4 
    Corticosteroid 2 
Operations  
    Tooth extraction / implantation 3 
    Subtotal thyroidectomy 1 
 
Of the 46 subjects who completed the study, six were excluded from data analysis due to the 
following reasons:  
1. One subject developed severe tonsillitis and took an antibiotic for five days. Visit 6 
had to be postponed for two weeks. 
2. One subject took an antibiotic for 10 days after a tooth implantation and analgesics 
multiple times throughout the study.  
3. Two subjects received corticosteroid injections due to orthopedic complaints. One of 
the subjects also had a bladder infection that was treated with antibiotics for 10 days. 
4. One subject had fluctuating TSH level outside the normal reference range after 
receiving a subtotal thyroidectomy. 
5. One subject was excluded due to violations of dietary instructions stated in section 
2.3.1. 
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3.3 Dietary composition 
 
The analysis of self-reported nutrient intakes from the four-day dietary reports indicated that 
subjects maintained an isocaloric diet in both diet periods (Table 9). Compared with the 
control diet, subjects significantly reduced the proportion of protein and carbohydrates and 
increased the proportion of fat in their diet during the walnut period. The composition of 
dietary fat differed significantly between the two diets. The percentage of SFA in the walnut 
diet was 12.3 ± 0.3% compared with 14.4 ± 0.4% in the control diet. The percentage of 
PUFA in the walnut diet was 14.1 ± 0.2% compared with 4.6 ± 0.2% in the control diet. The 
walnut diet also contained a significantly higher amount of ALA. The proportion of 
cholesterol was significantly lower in the walnut diet while dietary fiber and vitamin E did 
not differ between the two diets.   
 
Table 9. Dietary composition. 
 
Variable Walnut Diet Control Diet p* 
Total Energy (kcal)         2067 ± 53         2013 ± 63     0.294 
Fat (% of Total Energy) 39.2 ± 0.5  32.7 ± 0.6 < 0.001 
    Saturated fatty acids 12.3 ± 0.3 14.4 ± 0.4 < 0.001 
    Monounsaturated fatty acids 11.0 ± 0.2 11.3 ± 0.3    0.377 
    Polyunsaturated fatty acids 14.1 ± 0.2   4.6 ± 0.2 < 0.001 
         α-linolenic acid   2.4 ± 0.1   0.6 ± 0.1 < 0.001 
Protein (% of Total Energy) 15.1 ± 0.3 16.0 ± 0.4    0.018 
Carbohydrates (% of Total Energy) 43.5 ± 0.6 48.6 ± 0.7 < 0.001 
Cholesterol (mg/d) 260.8 ± 14.3 294.2 ± 13.2    0.013 
Fiber (g/d) 23.4 ± 1.1 23.5 ± 1.3    0.915 
Vitamin E (mg/d)   8.5 ± 0.4   9.1 ± 0.5    0.224 
Data are mean ± SEM. *Statistical significance set at p < 0.05 between the prescribed diets using two-tailed 
paired t-test or the Wilcoxon signed-rank test. 
 
3.4 Effect on anthropometric measurements and blood pressure 
 
Subjects maintained their baseline weight, BMI, waist circumference, and blood pressure 
during the study (Table 7).  
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3.5  Plasma fatty acids 
 
The plasma fatty acid profile showed a significant reduction in SFA as well as MUFA and an 
increase in PUFA (notably LA and ALA) after the walnut diet (Table 10). The walnut diet 
also significantly reduced arachidonic acid (AA), EPA, docosapentaenoic acids and DHA. 
The changes in plasma fatty acid constitution reflected the fatty acid composition of walnuts 
and confirmed the self-reported changes in fatty acid intake. This shows that subjects closely 
adhered to the prescribed diets. 
 
Table 10. Baseline plasma fatty acid profiles and changes from baseline.  
 
Fatty Acid Baselinew  ∆Walnut  Baselinec  ∆Control  p* 
Total SFA (%) 43.54 ± 0.17 -0.69 ± 0.14 43.15 ± 0.16  0.24 ± 0.13 < 0.0001 
   Myristic   0.61 ± 0.03  -0.10 ± 0.03   0.54 ± 0.03  0.06 ± 0.03   0.0008 
   Palmitic 28.46 ± 0.18 -0.89 ± 0.16 28.12 ± 0.17  0.28 ± 0.17 < 0.0001 
   Stearic 13.60 ± 0.14  0.39 ± 0.11 13.68 ± 0.14 -0.11 ± 0.14    0.0003 
Total MUFA (%) 14.03 ± 0.18 -2.33 ± 0.25 13.78 ± 0.21  0.10 ± 0.20 < 0.0001 
   Oleic 11.34 ± 0.17 -1.99 ± 0.22 11.16 ± 0.18  0.07 ± 0.18 < 0.0001 
Total PUFA (%) 42.43 ± 0.26      3.02 ± 0.31 43.07 ± 0.29 -0.35 ± 0.26 < 0.0001 
   Linoleic 21.58 ± 0.38  4.80 ± 0.40 22.70 ± 0.43 -0.57 ± 0.34 < 0.0001 
   α-linolenic   0.45 ± 0.06  0.10 ± 0.06   0.41 ± 0.05 -0.02 ± 0.06    0.0020 
   Arachidonic   9.49 ± 0.23 -0.64 ± 0.15   9.53 ± 0.24  0.01 ± 0.15    0.0034 
   Eicosapentaenoic   1.49 ± 0.13 -0.27 ± 0.10   1.29 ± 0.09  0.02 ± 0.07    0.0369 
   Docosapentaenoic   0.23 ± 0.01 -0.03 ± 0.02   0.21 ± 0.01 -0.01 ± 0.02    < 0.0001 
   Docosahexaenoic   3.99 ± 0.17 -0.38 ± 0.10   3.75 ± 0.15  0.10 ± 0.12    0.0098 
Fatty acid compositions are shown as percentage of the total amount of fatty acids measured.  
Data are mean ± SEM. Baselinew: baseline of walnut period; Baselinec: baseline of control period. ∆ denotes 
changes in each diet period; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; SFA: 
saturated fatty acids. * p-value of significance between walnut and controls determined using a mixed model 
and adjusted for age, gender, BMI, and diet sequence. 
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3.6 Effect on fasting lipids and apoB 
 
Fasting lipids and apoB are shown in Figure 12 and Table 11. Subjects were normolipidemic 
at baseline. The baseline values of lipid parameters did not differ significantly between the 
prescribed diets. A significant decrease in non-HDL-cholesterol was observed in the walnut 
period (-10 ± 3 mg/dL, p = 0.025) when compared with the control period (-3 ± 2 mg/dL). 
Similarly, the apoB concentration was significantly lowered by the walnut diet when 
compared with the control diet (-5.0 ± 1.3 mg/dL and -0.2 ± 1.1 mg/dL for walnut diet and 
control diet respectively, p = 0.009). The differences in treatment effect between the two diets 
on non-HDL-cholesterol and apoB remained significant after adjustment for gender, age, 
BMI and diet sequence. This analysis also indicates that age (p = 0.51), gender (p = 0.20), 
BMI (p = 0.80) and diet sequence (p = 0.33) did not affect the response to walnut 
consumption. The reduction in total cholesterol was -8 ± 3 mg/dL in the walnut period and     
-2 ± 2 mg/dL in the control period (difference p = 0.073). The walnut diet reduced               
LDL-cholesterol, VLDL-cholesterol, total triglycerides and VLDL triglycerides and 
increased HDL-cholesterol levels; however, these changes were non-significant when 
compared with those of the control period. Ratios of total cholesterol to HDL-cholesterol, 
LDL-cholesterol to HDL-cholesterol, and LDL-cholesterol to apoB at baseline were 3.2 ± 0.1, 
2.0 ± 0.1, and 1.5 ± 0.1 respectively and remained constant in both diet periods. 
 
 
Figure 12. Changes in fasting lipids and apolipoprotein B.  
Values are expressed as mean; error bars indicate SEM. *p ≤ 0.05, **p ≤ 0.01. ApoB: apolipoprotein B;     
HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; non-HDL-C:        
non-high-density lipoprotein cholesterol; TC: total cholesterol; TG: total triglycerides; VLDL-C: very- low-
density lipoprotein cholesterol; VLDL-TG: very-low-density lipoprotein triglycerides.  
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Table 11. Fasting plasma lipids and apolipoprotein B after dietary interventions. 
 
Variable Baselinew ∆ Walnut Baselinec ∆ Control  p* 
TC (mg/dL)            222 ± 4    -8 ± 3         219 ± 4   -2 ± 2 0.073 
LDL-C (mg/dL)            135 ± 4    -7 ± 3         133 ± 4    -2 ± 2 0.118 
HDL-C (mg/dL)                72 ± 2     2 ± 1  72 ± 2    1 ± 1 0.606 
VLDL-C (mg/dL)               15 ± 2    -3 ± 2   14 ± 2   -1 ± 1 0.120 
non-HDL-C (mg/dL)           150 ± 5  -10 ± 3         147 ± 4   -3 ± 2 0.025 
TG (mg/dL)               89 ± 6  -10 ± 5  84 ± 6   -2 ± 4 0.323 
VLDL-TG (mg/dL)               54 ± 5    -9 ± 5  51 ± 6   -3 ± 5 0.388 
ApoB (mg/dL)                  89.7 ± 2.4    -5.0 ± 1.3  87.4 ± 2.1    -0.2 ± 1.1 0.009 
Data are mean ± SEM. Baselinew: baseline of walnut period; Baselinec: baseline of control period. ∆ denotes 
changes in each diet period. ApoB: apolipoprotein B; HDL-C: high-density lipoprotein cholesterol; LDL-C: 
low-density lipoprotein cholesterol; non-HDL-C: non-high-density lipoprotein cholesterol; TC: total cholesterol; 
TG: total triglycerides; VLDL-C: very- low-density lipoprotein cholesterol; VLDL-TG: very-low-density 
lipoprotein triglycerides. * p-value of significance between walnut and controls determined using a mixed model 
and adjusted for age, gender, BMI, and diet sequence. 
 
3.7 Effect on fasting glucose metabolism, adipokines, CRP, endothelial function and 
biomarkers of endothelial dysfunction 
 
Parameters of fasting glucose metabolism (Table 12) were determined in a subgroup (n = 35). 
Fasting glucose, insulin, HOMA-IR, QUICKI and HbA1c remained stable in both diet 
periods (after adjustment for gender, age, BMI and diet sequence). Similarly, plasma leptin, 
adiponectin and chemerin concentrations as well as fasting VCAM-1, ICAM-1 and 
endothelin-1 remained stable in both diet periods after adjustment (Table 12). Plasma vaspin 
and visfatin concentrations were below the limit of detection of the standard assay. The 
median baseline CRP concentration was < 0.1 mg/dL (range: < 0.1-1.3 mg/dL). Furthermore, 
parameters of the endothelial function (RHI and fRHI) also did not change significantly. 
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Table 12. Parameters of glucose metabolism, adipokines, and  endothelial function after dietary interventions.  
 
Variable Baselinew ∆ Walnut Baselinec ∆ Control p* 
Fasting glucose (mg/dL) 92.1 ± 1.3 -0.7 ± 1.0 90.9 ± 1.4 1.3 ± 1.4 0.323 
Fasting insulin (µU/mL)     7.2 ± 0.66 0.48 ± 0.45 6.83 ± 0.58 1.56 ± 0.58 0.169 
QUICKI   0.363 ± 0.005 -0.003 ± 0.005   0.369 ± 0.006 -0.015 ± 0.005 0.103 
HOMA-IR   1.79 ± 0.19 0.06 ± 0.13 1.65 ± 0.17  0.35 ± 0.16 0.200 
HbA1c (%)   5.47 ± 0.04 0.06 ± 0.03 5.55 ± 0.04 -0.02 ± 0.04 0.232 
Leptin (ng/ml)       18.7 ± 2.5 -1.5 ± 1.2  14.2 ± 2.0   -0.4 ± 0.8 0.709 
Adiponectin (μg/mL) 23.3 ± 1.6     -1.0 ± 1.2 21.8 ± 1.5 1.3 ± 1.1 0.221 
Chemerin (ng/mL) 220.1 ± 12.1 8.2 ± 7.0 233.8 ± 11.9 -2.8 ± 6.4 0.370 
VCAM-1 (ng/mL) 605.8 ± 26.5 23.8 ± 40.9 601.3 ± 27.3 12.3 ± 24.7 0.733 
ICAM-1 (ng/mL)     203.4 ± 6.6 -2.3 ± 7.2 208.1 ± 6.3 -1.3 ± 5.1 0.815 
Endothelin-1 (pg/mL)   1.5 ± 0.1   -0.1 ± 0.1 1.4 ± 0.1 -0.1 ± 0.1 0.965 
RHI   2.09 ± 0.10 -0.07 ± 0.10 1.92 ± 0.10 0.05 ± 0.08 0.724 
fRHI   0.51 ± 0.06 -0.06 ± 0.07 0.42± 0.06 0.13 ± 0.07 0.174 
Data are mean ± SEM. Baselinew: baseline of walnut period; Baselinec: baseline of control period. ∆ denotes 
changes in each diet period. fRHI: Framingham-reactive hyperemia index; HOMA-IR: homeostasis model 
assessment estimate of insulin resistance; ICAM-1: intercellular adhesion molecule-1; QUICKI: quantitative 
insulin-sensitivity check index; RHI: reactive hyperemia index. VCAM-1: vascular cell adhesion molecule-1.     
* p-value of significance between walnut and controls determined using a mixed model and adjusted for age, 
gender, BMI, and diet sequence. 
 
3.8 Effect on postprandial lipid and glucose metabolism   
 
The effect on postprandial lipid and glucose metabolism was evaluated in a subgroup (n = 32). 
As shown in Table 13, changes in AUC and iAUC of total triglycerides,              
chylomicron-triglycerides, VLDL-triglycerides, glucose, and insulin were non-significant. 
Similarly, the treatment x time interaction was also non-significant for any of the parameters, 
indicating that the shape of the curve also did not change. 
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Table 13. Postprandial lipid and glucose metabolism after dietary interventions. 
 
Variable Baselinew ∆ Walnut Baselinec ∆ Control p* 
AUC      
   TG (mg x h/dL) 1023 ± 79 -30 ± 55  1066 ± 86   -52 ± 50 0.936 
   CM-TG (mg x h/dL)   243 ± 32    4 ± 24   246 ± 27   -12 ± 16 0.582 
   VLDL-TG (mg x h/dL)   572 ± 69   -5 ± 46   593 ± 71     -4 ± 44 0.831 
   Glucose (mg x h/dL)         370 ± 8  4 ± 8   368 ± 11       -6 ± 107 0.260 
   Insulin (µU x h/mL)   110 ± 15  1 ± 6   89 ± 10  15 ± 7 0.199 
iAUC      
   TG (mg x h/dL)   354 ± 41  17 ± 36    381 ± 34         -16 ± 22  0.386 
   CM-TG (mg x h/dL)   214 ± 29   -3 ± 23   213 ± 24    -8 ± 15 0.834 
   VLDL-TG (mg x h/dL)   192 ± 24  24 ± 25   191 ± 18   25 ± 14 0.971 
   Glucose (mg x h/dL)   23 ± 8          -1 ± 8     25 ± 10  -23 ± 13 0.053 
   Insulin (µU x h/mL)     84 ± 12 1 ± 6   64 ± 8   6 ± 7 0.528 
Data are mean ± SEM. Baselinew: baseline of walnut period; Baselinec: baseline of control period. ∆ denotes 
changes in each diet period. AUC: area under the curve; iAUC: incremental area under the curve. CM-TG: 
chylomicron triglycerides; TG: total triglycerides; VLDL-TG: very-low-density lipoprotein triglycerides.            
* p-value of significance between walnut and controls determined using a mixed model and adjusted for age, 
gender, BMI, and diet sequence. 
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4 DISCUSSION 
 
The present study showed that an eight-week daily supplementation of 43 g of walnuts 
significantly reduced fasting non-HDL-cholesterol and apoB levels in healthy senior 
individuals, even after adjustment for gender, age, BMI, and diet sequence. Postprandial lipid 
metabolism, glucose metabolism, circulating levels of adipokines and CRP, endothelial 
function, body weight, and blood pressure remained unaffected. Each of the analyzed 
parameters will be discussed in detail in the following sections.  
 
4.1 Diets and plasma fatty acids 
 
During the 20-week study period, dietary adherence was closely monitored using diet 
protocols completed by subjects at regular intervals. The walnut diet was well tolerated and 
no adverse effect was reported. The amount of walnuts used in this study was selected 
because 43 g/d (approximately 1.5 ounces/d) is the amount needed to meet the qualified 
health claim issued by the U.S. Food and Drug Administration for walnuts (76).  
 
Walnuts are energy-dense food with high satiating capacities. There is evidence supporting 
that nut consumption may modulate appetite and promote the feeling of fullness (77). 
Although subjects maintained an isocaloric diet throughout the study, macronutrient 
distribution differed significantly between the walnut and the control diet. Subjects consumed 
more fat, specifically PUFA, and less carbohydrate and protein in the walnut phase. Previous 
nut studies have also reported such compensatory dietary response that maintains energy 
balance (78-80).  
 
Many beneficial effects of walnuts have been attributed to their high PUFA content. 
Compared with a traditional Mediterranean diet, a typical Western-type diet consists of a 
lower amount of PUFA and a higher amount of SFA. Dietary guidelines from the Food and 
Agriculture Organization of the United Nations and the World Health Organization 
recommend a consumption of SFA < 10% of total energy and a consumption of PUFA 6-11% 
of total energy (81). An analysis of dietary fat intake in 40 countries, mostly developed 
countries, showed that only 11 countries met the dietary recommendation for SFA and 20 
countries met the recommendation for PUFA. In Germany, more than 80% of the studied 
population deviated from the recommendation on SFA intake, and close to 40% of the 
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population did not meet the recommendation on PUFA intake. The average PUFA intake in 
Germany (6.5% of total energy) was on the lower end of the recommended range, and ALA 
only made up 0.8% of total energy (82). In the present study, subjects did not meet the 
aforementioned dietary recommendations for SFA and PUFA intake in the control phase, but 
there was a slight but significant decrease in SFA and a marked increase in PUFA intake in 
the walnut phase. ALA was also raised from 0.6% to 2.4% of total energy. This confirms that 
walnuts are an excellent source of PUFA. Mozaffarian et al. showed in a meta-analysis that 
for each 5% energy derived from increased PUFA intake, the CHD risk was decreased by 10% 
(83).    
 
LA is the major n-6 PUFA in walnuts. After the walnut diet, subjects of this study had 
significantly more LA in plasma, but the amount of AA, a downstream metabolite of LA, 
decreased significantly. AA is the precursor of the majority of eicosanoids. The production of 
proinflammatory eicosanoids has led to the speculation that higher LA intake may raise the 
AA level and induce a proinflammatory milieu that increases the risk of CVD and causes 
other health problems. As observed in this study, an increased plasma level of LA did not 
lead to an increase in plasma AA level. Other studies have shown that changes in LA intake 
appear not to significantly affect tissue AA content (84). Kinetic studies have observed that 
only 0.2% of LA is converted to AA (85). It is possible that a diet with increased ALA intake 
may hamper the conversion of LA to AA by competing for the same rate-limiting enzyme, 
∆6-desaturase, which is involved in the synthesis of AA, EPA, and DHA (86, 87).   
 
To date, clinical data have not confirmed this hypothesized risk of LA to induce 
inflammation and promote CVD. On the contrary, there is accumulating evidence suggesting 
a cardio-protective effect of LA. In a meta-analysis of prospective cohort studies, Farvid et al. 
showed a dose-dependent inverse relationship between LA intake and CHD. A 5% increase 
in energy derived from LA in place of SFA was linked to a 9% decreased risk of total CHD 
and a 13% decreased risk of CHD deaths (88). In a prospective cohort study involving 60-
year-old Swedish men and women without prior CVD, Marklund et al. observed an inverse 
relationship between serum LA levels determined at baseline and all-cause mortality in men 
(43). These results lend support to the dietary guidelines that advocate a diet rich in PUFA 
(81).   
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4.2 Body weight  
 
Contrary to the popular belief that increased consumption of dietary fat may lead to weight 
gain, subjects of this study maintained their baseline weight, most likely due to the isocaloric 
nature of the walnut diet. This is in line with a number of studies showing that nut 
consumption does not have detrimental effects on body weight and waist circumference. In 
fact, some studies have shown that regular nut intake may even promote weight loss (89, 90). 
There is some evidence suggesting that walnuts may induce fat oxidation (91), promote 
postprandial thermogenesis (92), and lower body fat mass (93, 94). Furthermore, the total 
energy content of walnuts listed in food composition tables may, in fact, overestimate the 
actual metabolizable energy content. Baer et al. showed that the energy value of walnuts 
calculated using the Atwater system, which is widely used to determine the available energy 
of foods, exceeded the measured value by 21% (40). An overestimation of the metabolizable 
energy using the Atwater system had also been previously reported for other nuts such as 
almonds (95) and pistachios (96). The Atwater system may be inadequate for calculating the 
energy value of nuts due to the lower digestibility of fat in whole nuts when compared with 
other food groups (95). The decreased digestibility of fat from nuts results in increased fecal 
fat content, which may explain, in part, the fact that the actual energy available to the body is 
lower than the estimated energy (40).   
 
4.3 Lipid metabolism 
 
The results showed that walnut consumption significantly decreased fasting                       
non-HDL-cholesterol and apoB levels. Total cholesterol showed a trend toward reduction, 
and the cholesterol content of LDL, VLDL, and HDL as well as total triglycerides all 
improved despite statistically non-significant differences. Using a predictive model that 
assesses the effects of quantitative changes in dietary intake of fatty acids (SFA, PUFA, 
MUFA) and cholesterol on plasma total cholesterol and cholesterol fractions (97), changes in 
total cholesterol, LDL, and HDL were estimated to be -14.1 mg/dl, -11.0 mg/dl and                
-1.1 mg/dl, respectively. The calculations provide information on the relative contribution of 
the changes in dietary fatty acids on the observed reduction in plasma cholesterol levels. The 
cholesterol-lowering effect of walnuts may be largely attributed to the increase in PUFA 
(9.2%), since SFA intake only decreased slightly (-2.4%), and MUFA intake remained 
unaffected. The decreased dietary cholesterol had a negligible effect on plasma cholesterol 
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(97). Compared with the predicted values, the actual changes were lower. An earlier study 
demonstrated that the measured change in LDL-cholesterol exceeded the predicted change 
for a walnut-supplemented diet; however, the study subjects were hypercholesterolemic at 
baseline (98). Numerous feeding trials have reported a greater reduction in total cholesterol 
and LDL-cholesterol in hypercholesterolemic individuals. A pooled analysis of 25 feeding 
trials concluded that nut consumption reduced triglycerides only in hypertriglyceridemic 
subjects and reduced cholesterol concentration in a dose-dependent manner, with the largest 
decrease observed in individuals with higher baseline LDL or lower BMI as well as in those 
following a Western diet (compared with a Mediterranean and a low-fat diet) (34). Subjects 
of the current study were normolipidemic at baseline and received a comparatively lower 
amount of walnuts. Thus, changes in lipoprotein levels may be of smaller magnitude than 
those in subjects with dyslipidemia. 
 
Currently, LDL-cholesterol remains to be the primary treatment target, while                    
non-HDL-cholesterol and apoB are still considered secondary treatment targets. However, 
there is increasing evidence suggesting that non-HDL-cholesterol and apoB may be superior 
to LDL-cholesterol in the evaluation CVD risk (99-101). Both non-HDL-cholesterol and 
apoB encompass the cholesterol content of all atherogenic lipoproteins. In patients treated 
with statins, non-HDL-cholesterol, apoB and LDL-cholesterol all predicted future 
cardiovascular events, but the predictive value of non-HDL-cholesterol was greater than the 
other two parameters (102). Based on a meta-analysis of various lipid-modifying therapies 
that showed a 1:1 relationship between the percentage decrease in non-HDL-cholesterol and 
the risk reduction of CHD (103), the decrease in non-HDL-cholesterol for the walnut diet in 
the current study can be translated to a predicted 6.7% risk reduction, which resonates with 
the findings of the PREDIMED trial (63). The inverse relationship between walnut 
consumption and levels of atherogenic lipoproteins can serve as a potential explanation for 
the observed beneficial effects of nuts on CVD outcomes. 
 
The cardioprotective effects of walnuts have been largely attributed to their high PUFA 
content. Walnuts contain abundant LA (n-6 PUFA) and ALA (n-3 PUFA), both of which are 
considered essential fatty acids because they cannot be made by humans. More than 50 years 
ago, H.M. Sinclair reported that the absence of essential fatty acids may have detrimental 
effects on vascular health. He proposed the hypothesis that the quantity and the structure of 
the dietary fatty acids may be more important than the amount of total fat ingested (104). 
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This idea is also reflected in the dietary guidelines that recommend replacing SFA with 
PUFA (81, 105).  
 
The exact mechanisms underlying the cholesterol-lowering effects of PUFA are still unclear. 
It is most likely that PUFA exert their favourable effects via a number of different 
mechanistic actions. At the cellular level, PUFA can alter the fatty acid composition of 
membrane phospholipids, thus changing the microenvironments in which biological reactions 
take place. Changes in membrane phospholipid composition can modify the physical 
properties of the cellular membrane, such as its structure and fluidity, which in turn affect the 
structure and function of proteins and receptors embedded in the membrane. Furthermore, 
PUFA can act as second messengers, thus regulating intracellular signaling pathways. The 
PUFA released from membrane phospholipids can also function as signaling molecules, 
regulate gene expression by binding to transcription factors, and act as precursors for lipid 
mediators (106). 
 
The favourable lipid profile of nuts cannot entirely account for the cholesterol-lowering 
effects observed in clinical studies. When the actual changes in lipoprotein levels were 
compared with estimated changes calculated using predictive equations, the actual changes 
exceeded predicted changes by approximately 25%. Nuts contain an array of other nonfat 
nutrients such as plant proteins, dietary fiber, phytosterols, tocopherols, phenolic compounds 
and minerals that may confer additional beneficial effects on plasma lipids. However, there is 
limited information on the quantity and bioaccessibility of these compounds and their relative 
contribution to the improvement of plasma lipid profile (107).  
 
Phytosterols are plant-derived sterols that share structural and functional similarities with 
cholesterol. Unlike cholesterol, the plasma phytosterol levels are low due to poor intestinal 
absorption (108). Phytosterols may reduce plasma cholesterol levels by competitively 
inhibiting the intestinal absorption of cholesterol and by modulating the expression of hepatic 
and intestinal genes involved in lipid metabolism (49). The underlying mechanisms may be 
explained by the relatively higher hydrophobicity of phytosterols, which display a greater 
affinity for micelles than cholesterol, thus displacing cholesterol from micelles and lowering 
the intestinal absorption of cholesterol (109). In addition, dietary fiber and plant protein have 
also been suggested to elicit cholesterol-lowering effects (110). Walnuts contain relatively 
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large amounts of arginine, an amino acid that may have a beneficial effect on lipid 
metabolism (111, 112). 
 
Many questions regarding the mechanisms underlying the cholesterol-lowering effects of 
walnuts still remain to be answered. This study showed that the improvement in lipid profile 
may be mediated by changes in apoB metabolism. This raises the question whether the 
reduction in apoB concentration is a result of decreased production or increased clearance of 
apoB-containing lipoproteins or a combination of both. One study showed that walnuts may 
facilitate the clearance of LDL. LDL particles obtained from hypercholesterolemic men 
during a six-week walnut-enriched diet had 50% increased association rates with LDL 
receptors of cultured human hepatoma cells when compared with LDL particles isolated 
during the control diet. The binding of LDL particles to LDL receptors was correlated with 
the ALA content of the LDL lipid core. However, the increased LDL association only 
explained about 30% of the observed LDL reduction, suggesting that additional factors may 
contribute to the overall cholesterol-lowering effects (113). Further research is needed to 
understand the biochemical processes underlying the lipid changes induced by walnut 
consumption.  
 
This study did not observe a significant change in triglycerides in both the walnut and the 
control diet. To date, the triglyceride-lowering effect of marine-based n-3 PUFA has been 
well-established. Marine-based n-3 PUFA, known as EPA and DHA, differ from plant-based 
n-3 PUFA, ALA, in structure and effect. EPA and DHA are both long-chain PUFA that lower 
fasting triglyceride levels and improve postprandial lipemia. The underlying mechanisms 
have been suggested to involve the activation of certain transcription factors in the liver, 
resulting in an increased expression of genes encoding enzymes needed for beta-oxidization 
and a decreased expression of genes encoding enzymes involved in lipogenesis, consequently 
reducing the hepatic availability of fatty acids for VLDL assembly (114). In addition, data 
from kinetic studies have shown that long-chain n-3 PUFA decrease the rate of production 
and direct catabolism of non-fasting hepatic and intestinal-derived apoB (115). Long-chain  
n-3 PUFA do not seem to affect levels of total cholesterol and LDL-cholesterol in individuals 
with normal lipid levels. However, people with certain types of dyslipidemia such as elevated 
triglyceride levels and decreased HDL-cholesterol levels may exhibit a considerable increase 
in LDL-cholesterol levels after EPA and DHA supplementation. In contrast, plant-based 
foods rich in ALA have been shown to reduce plasma levels of cholesterol but not 
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triglycerides. The disparate effects between long-chain n-3 PUFA and ALA have been 
attributed to their difference in chain length (116). Although ALA is the metabolic precursor 
of EPA and DHA, the conversion in humans is rather inefficient (117), which could explain 
the lack of increase in long-chain n-3 PUFA levels and the lack of changes in both fasting 
and postprandial triglyceride levels observed in this study. 
 
4.4 Glucose metabolism  
 
Both experimental diets did not change parameters of fasting and postprandial glucose 
metabolism. Past epidemiological studies have suggested that regular nut intake may reduce 
the risk of developing diabetes. Data from the Nurses’ Health Study I were analyzed to 
determine the relationship between nut intake and type-2 diabetes. The study included 83,818 
women between the age of 34 and 59 years with no history of diabetes and CVD. The authors 
reported an inverse relationship between nut intake and risk of type-2 diabetes after 
adjustment for age, BMI, family history of diabetes, physical activity, smoking, alcohol 
consumption, and total energy intake as well as other dietary factors. Women whose nut 
intake was at least five times a week compared with those who never or seldom ate nuts had a 
relative risk of diabetes 0.74 (95% confidence interval, 0.61-0.89) (118). In the follow-up 
study in 2013, Nurses’ Health Study II once again confirmed the inverse relationship between 
nut consumption and type-2 diabetes. Of note is that among the studied tree nuts, walnut 
consumption was associated with the lowest risk. After adjustment for BMI, women who ate 
more than two servings of walnuts each week in comparison with those who never or rarely 
ate walnuts had a hazard ratio of 0.76 (95% confidence interval, 0.62–0.94). While the other 
tree nuts were also associated with reduced risk of type-2 diabetes, the relationship was 
insignificant after adjustment for BMI (119). 
 
Despite a clear inverse relationship between nut intake and diabetes shown in 
epidemiological studies, results from feeding trials have shown inconsistent findings 
regarding the effect of walnuts on parameters of glucose metabolism. A subanalysis of the 
PREDIMED trial showed that the Mediterranean diet enriched with mixed nuts (50% walnuts) 
demonstrated a lower incidence of type-2 diabetes in subjects who did not have the disease at 
enrollment but had a high CVD risk profile (120). Casas-Agustench et al. observed that a    
12-week supplementation of 30 g/d of mixed nuts (15g of walnuts) decreased fasting insulin 
and HOMA-IR (121). Another study by Kalgaonkar showed a decrease in HbA1c and an 
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improvement in insulin response to an oral glucose tolerance test in women with polycystic 
ovary syndrome after following a walnut-enhanced diet for six weeks (122). Yet several other 
feeding trials reported that glucose metabolism was unaffected by walnut consumption in 
subjects with type-2 diabetes and metabolic syndrome (94, 123, 124). The lack of change in 
fasting and postprandial glucose metabolism observed in the present study may be due to the 
short study intervention period and the low-risk profile of the study subjects.  
 
4.5 Adipokines 
 
A limited number of studies have explored the effect of walnut consumption on plasma 
adipokines. In the present study, the adipokine levels were unaffected by the walnut diet. In 
contrast, previous studies have reported a positive effect on plasma adiponectin concentration 
in subjects who either had or were at risk of developing type-2 diabetes. Aronis et al. found 
that short-term consumption of walnuts (four days) resulted in a significant increase in total 
adiponectin level in obese individuals with metabolic syndrome (125). Kalgaonkar et al. also 
reported an increase in adiponectin in women with polycystic ovary syndrome after six weeks 
of walnut intake (122). A traditional Mediterranean diet has been shown to associate with 
higher plasma adiponectin level in diabetic women (126). Adiponectin exhibits insulin-
sensitizing and antiatherogenic properties, and its plasma level is inversely associated with 
weight loss (127). Subjects in the present study did not exhibit changes in adipokine levels. 
This could be explained by the fact that they were non-obese at baseline, and their body 
weight remained stable throughout the study.  
 
4.6 Inflammation, endothelial function and blood pressure 
 
Inflammation plays a crucial role in the development and progression of atherosclerotic 
disease. Increased plasma levels of inflammatory markers are associated with elevated risk 
for cardiovascular events (128, 129). CRP is a well-known marker of systemic inflammation. 
There is evidence showing that the prognostic value of CRP level is comparable to that of 
cholesterol levels in assessing cardiovascular risk (130). Because walnuts contain abundant 
nutrients that confer anti-inflammatory effects, the present study measured plasma CRP level 
before and after dietary interventions. The walnut and the control diet did not have an effect 
on CRP level.  
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Previous studies have reported inconsistent findings regarding the effect of walnut 
consumption on CRP level. Ros et al. found that CRP level remained constant in 
hypercholesterolemic individuals after a four-week walnut-enriched diet (131). In another 
study, a high ALA diet achieved through the supplementation of walnuts, walnut oil, and 
flaxseed oil significantly improved CRP and markers of endothelial activation (44). In 
contrast to these two studies, Mukuddem-Petersen et al. reported a significant increase in 
CRP level after a walnut diet in subjects with metabolic syndrome; however, this trial had a 
parallel design, and despite a significant increase after the walnut diet, the CRP level in the 
walnut group was still lower compared with that of the control groups (123). It could be 
argued that an improvement in CRP may not be apparent in the present study because the 
baseline level was already very low. Despite a lack of change in CRP level, the potential anti-
inflammatory effects of walnuts cannot be dismissed, since walnuts appear to reduce other 
inflammatory markers such as tumor necrosis factor-α (132) and interleukin-6 (133). 
 
Inflammatory processes are accompanied by the concurrent increase in cellular adhesion 
molecules (4), which act as circulating markers of endothelial dysfunction (134). Zhao et al. 
observed that walnut consumption significantly reduced plasma levels of ICAM-1 but not 
VCAM-1 (135). In two other studies, both VCAM-1 and ICAM-1 decreased significantly (44, 
133). Several studies have also demonstrated an improvement in endothelial function 
assessed using brachial artery FMD. In contrast to previous studies, the present study did not 
observe changes in markers of endothelial dysfunction (VCAM-1, ICAM-1, and      
endothelin-1). Moreover, the postprandial endothelial function assessed using PAT remained 
unaffected. 
 
Lopez-Uriate et al. (136) and Berry et al. (137) also demonstrated that finger arterial pulse 
wave amplitude was not affected by nut consumption. Interestingly, various walnut 
components may exhibit different effects when compared with whole walnuts, as seen in a 
study that showed a favourable change in fRHI after acute consumption of walnut oil when 
compared with walnut skin and whole walnuts. This was attributed to the higher 
bioavailability of nutrients in walnut oil (138). 
 
In the current study, there was great intraindividual variability in the PAT measurements in 
both the walnut and the control phase. Low interday reproducibility of RHI was observed in 
one study by Liu et al. who repeated the PAT measurements in 10 healthy men at fixed time 
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points for 3 consecutive days. It is unclear what causes the variability in PAT measurements. 
The endothelial response assessed by PAT is affected by many internal and environmental 
factors (139). Daily changes in these factors may affect the peripheral arterial response.    
 
The PAT measurements may not be directly comparable to the results of previous studies 
because of the differences in study population and the methodology used. An improvement in 
brachial artery FMD was previously observed in hypercholesterolemic subjects after a four-
week walnut diet and even after just a single walnut-enriched meal (131). Although both 
FMD and PAT are non-invasive methods of assessing the endothelial function, there is a lack 
of consistent correlation between PAT and FMD measurements. This suggests that each 
method may assess different changes in vascular function (140). Despite some studies 
showing that NO plays a central role in both methodologies (141, 142), it is believed that 
PAT is a measure of microvascular function, which is mainly endothelium-independent, 
whereas FMD is a measure of macrovascular function (143).   
 
Because subjects of this study were at low risk of developing CVD, the effect of walnuts on 
inflammation, endothelial function, and blood pressure may not be apparent. Subjects of this 
study had blood pressure within normal range. The PREDIMED study showed in individuals 
at high risk of developing CVD that long-term Mediterranean diet with olive oil or nuts 
improved blood pressure. The improvement in diastolic pressure was greater in the 
Mediterranean diet groups than in a low-fat control group (144). A meta-analysis of 21 
randomized controlled trials with a total of 1652 individuals showed that nut intake did not 
change systolic blood pressure significantly. However, subgroup analyses showed that nut 
consumption significantly reduced systolic blood pressure in non-diabetic individuals (145). 
Long-term studies are needed to assess the preventive effects of walnuts on inflammation, 
endothelial dysfunction, and hypertension.  
 
4.7 Strengths and limitations 
 
Among the major strengths of this study is its randomized, cross-over design with the 
addition of a wash-out period. The study systematically assessed the effect of walnut 
consumption on both fasting and postprandial lipid and glucose metabolism, circulating 
levels of adipokines and CRP, endothelial function, blood pressure, and body weight in 
healthy senior individuals. The study also has several limitations including a small sample 
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size, a short intervention period, and the underrepresentation of men. The majority of the 
study subjects were women so that an inter-gender comparison was not possible. Moreover, 
this study only included Caucasians. Different populations may respond to the dietary 
interventions differently. This may limit the generalizability of the results in this study. 
However, cholesterol-lowering effects of walnuts have also been observed in Japanese 
individuals (67). Furthermore, the background diet of this study was not standardized. The 
study also did not include an ad libitum dietary intervention, since walnuts replaced other 
foods. The influence of other food items (either added or omitted) cannot be completely ruled 
out. There was large variability in the response of study subjects to the dietary interventions, 
with some showing a large reduction in cholesterol and triglyceride levels while others 
exhibiting only small changes. The individual responsiveness to dietary interventions may be 
affected by other factors such as genetic makeup. It is important to note that subjects of this 
study were at low risk of developing CVD, thus other beneficial effects of walnuts may have 
been masked. Another limitation of this study is that only a subgroup analysis of postprandial 
metabolism was conducted. Due to the lack of elevation in postprandial triglyceride levels 
after using the initial test drink A (32 g of fat), the fat content was raised to 88 g in test drink 
B. One of the challenges of conducting postprandial trials is that no standardized test meal is 
available (146). The relatively small sample size in the postprandial test reduced the power of 
the postprandial analysis.  
 
4.8 Conclusions 
 
Previous studies have consistently demonstrated that walnut consumption improves lipid 
profile in hypercholesterolemic subjects. Results of the present study extend this finding to 
healthy senior individuals. Dietary modification is an integral component in the prevention of 
dyslipidemia, a well-established independent risk marker of CVD. This study shows that 
supplementing 43 g of walnuts for eight weeks favourably changed plasma lipid profile by 
lowering the concentration of non-HDL-cholesterol and apoB, which may explain, in part, 
the epidemiological observation that walnut consumption reduces the risk of CVD.  
Currently, the mechanistic actions of walnuts are still unclear. Information regarding the 
bioavailability and bioaccessibility of the micronutrients in walnuts is scarce. The 
cardioprotective effects of walnuts are most likely not the product of a single nutrient but 
rather different nutrients working synergistically. Further research is warranted to explore the 
composition of walnuts and the underlying mechanisms of their beneficial effects. 
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5 SUMMARY 
 
Cardiovascular disease (CVD) is the leading cause of death worldwide. Although there has 
been a trend showing a decline in CVD mortality in developed countries, a staggering 
increase has been observed in medium- and low-income countries. Excluding genetic factors, 
most CVD risk factors are modifiable. Dietary modification is an important component of 
CVD management and prevention. The amount and the types of food eaten have great 
influence on a person’s health. In the last half-century, there has been growing interest in 
identifying healthy dietary patterns and finding so-called “functional foods”. Nuts, especially 
walnuts, have garnered wide attention.  
 
Walnuts are nutrient-dense foods with a unique fatty acid profile. While most nuts are high in 
monounsaturated fatty acids, walnuts are predominantly composed of polyunsaturated fatty 
acids (47% of total weight), mainly linoleic acid and alpha-linolenic acid. Walnuts are also 
the only nuts with a significant amount of alpha-linolenic acid, which has been shown to 
elicit anti-inflammatory and anti-atherogenic effects. Beyond the favourable fatty acid profile, 
walnuts also contain other potentially cardioprotective nutrients such as plant protein, dietary 
fiber, polyphenols, phytosterols, and tocopherols. Epidemiological studies have consistently 
shown an inverse relationship between nut consumption and CVD. Previous clinical studies 
involving walnuts were mostly conducted in individuals at increased risk of developing CVD.  
 
This randomized, controlled, and cross-over study investigated the effect of walnut 
consumption on fasting and postprandial lipid and glucose parameters, adipokines, CRP, 
blood pressure, body weight, and endothelial function in healthy men and healthy 
postmenopausal women. Data from 40 subjects (mean ± standard error of mean: age            
60 ± 1 years, BMI 24.9 ± 0.6 kg/m
2
; 30 females) ≥50 years old were analyzed. Two test diets 
were used. The background diet was composed of a Western-type diet (35 % fat, of which  
15 % saturated fatty acids, 15 % protein, and 50 % carbohydrate). The two diets were 
identical except that subjects were asked to replace 30 g of saturated fat with 43 g of shelled, 
prepackaged walnuts in the walnut phase. Diet protocols were completed at regular intervals. 
After a two-week nut-free run-in period, each diet lasted eight weeks, and the two diets were 
separated by a two-week wash-out. At the beginning and end of each diet phase, a physical 
examination, a mixed meal test, and a non-invasive assessment of postprandial endothelial 
function were conducted. Blood was drawn at 0 (fasting), 15, 30, 60, 120, 180, 240, 360, and 
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480 minutes. Total cholesterol, LDL-cholesterol, HDL-cholesterol, total triglycerides, 
VLDL-triglycerides, apoB, glucose, insulin, HOMA-IR, QUICKI, HbA1c, adipokines, 
biomarkers of endothelial dysfunction (VCAM-1, ICAM-1 and endothelin-1) and CRP were 
determined in fasting samples. Fasting non-HDL-cholesterol was calculated using the 
equation total cholesterol - HDL-cholesterol. Area under the curve (AUC) and incremental 
AUC (iAUC) were calculated for postprandial total triglycerides, VLDL-triglycerides, 
chylomicron-triglycerides, glucose, and insulin. 
 
Compared with the control diet, the walnut diet significantly reduced non-HDL-cholesterol 
(walnut vs. control: -10 ± 3 vs. -3 ± 2 mg/dL; p = 0.025) and apoB (-5.0 ± 1.3 vs.                      
-0.2 ± 1.1 mg/dL; p = 0.009). These findings remained significant after adjusting for age, 
gender, body mass index, and diet sequence. Total cholesterol showed a trend toward 
reduction (p = 0.073). Fasting VLDL-cholesterol, LDL-cholesterol, HDL-cholesterol, 
triglycerides and glucose, insulin, HOMA-IR, QUICKI, and HbA1c did not change 
significantly. Similarly, fasting adipokines, CRP, biomarkers of endothelial dysfunction, 
postprandial lipid and glucose metabolism (AUC and iAUC), and endothelial function were 
unaffected. 
 
This study showed that supplementing 43 g of walnuts for eight weeks favourably changed 
plasma lipid profile by lowering the concentration of non-HDL-cholesterol and apoB. The 
short-term walnut consumption did not affect glucose metabolism, circulating levels of 
adipokines and CRP, as well as endothelial function, body weight, and blood pressure. The 
favourable changes in plasma lipid profile may explain, in part, the epidemiological 
observation that walnut consumption reduces the risk of CVD.  
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6 ZUSAMMENFASSUNG 
 
Kardiovaskuläre Erkrankungen sind die weltweit führende Todesursache. Obwohl in den 
Industrieländern die kardiovaskuläre Mortalität abnimmt, wurde ein deutlicher Anstieg der 
Mortalität in Mittel- und Niedrigeinkommensländern beobachtet. Außer den genetischen 
Faktoren sind die meisten kardiovaskulären Risikofaktoren modifizierbar. Dietätische 
Modifikation ist ein wichtiger Bestandteil der Therapie und Prävention von kardiovaskulären 
Erkrankungen. Art und Menge der verzehrten Nahrung haben großen Einfluss auf die 
Gesundheit. In den letzten fünfzig Jahren ergab sich ein wachsendes Interesse bei der 
Ermittlung von gesunden Ernährungsmustern und bei der Suche nach so genanntem 
"Functional Food“. Nüsse, insbesondere Walnüsse, haben hierbei große Aufmerksamkeit 
erregt. 
 
Walnüsse sind nährstoffreiche Lebensmittel mit einem einzigartigen Fettsäureprofil. Im 
Vergleich zu anderen Nüssen, die überwiegend reich an einfach-ungesättigten Fettsäuren sind, 
enthalten Walnüsse große Mengen an mehrfach-ungesättigten Fettsäuren (47% des 
Gesamtgewichts), vorwiegend Linolsäure und alpha-Linolensäure. Walnüsse sind die 
einzigen Nüsse mit signifikanten Mengen an α-Linolensäure, welche antientzündliche und 
antiatherogenen Wirkungen aufweisen. Zudem liefern Walnüsse weitere potentielle 
kardioprotektive Inhaltsstoffe wie pflanzliches Protein, Ballaststoffe, Polyphenole, 
Phytosterine, und Tocopherole. Epidemiologische Studien zeigen eine inverse Beziehung 
zwischen Nusskonsum und kardiovaskulären Erkrankungen. Bisherige klinische Studien mit 
Walnüssen wurden meist bei Personen mit einem erhöhten kardiovaskulären Risiko 
durchgeführt.       
 
Diese randomisierte, kontrollierte Cross-over-Studie untersuchte den Effekt des 
Walnusskonsums auf nüchtern und postprandialen Lipid- und Glukosestoffwechsel, 
Adipokine, CRP, Blutdruck, Körpergewicht sowie die Endothelfunktion bei gesunden 
Männern und gesunden postmenopausalen Frauen. Daten von 40 Probanden (Mittelwert ± 
Standardfehler: Alter 60 ± 1 Jahre, BMI 24.9 ± 0.6 kg/m
2
, 30 Frauen) ≥ 50 Jahre wurden 
analysiert. Zwei Testdiäten wurden verwendet. Die Hintergrunddiät bestand aus einer 
westlichen Diät-Typ (35 % Fett, davon 15 % gesättigte Fettsäuren, 15 % Proteine and 50 % 
Kohlenhydrate). Die zwei Testdiäten waren bis auf die Tatsache identisch, dass die 
Probanden in der Walnuss-Phase 30 g gesättigte Fettsäuren durch 43 g geschälte, 
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vorverpackte Walnüssen ersetzten. Ernährungsprotokolle wurden in regemäßigen Abständen 
ausgefüllt. Nach einer zweiwöchigen, nussfreien „Run-in“-Periode, dauerte jede Diät acht 
Wochen und beide Diäten wurden durch eine zwei-wöchige Auswaschphase getrennt. Zu 
Beginn und am Ende jeder Diätphase erhielten die Probanden eine körperliche Untersuchung, 
eine standardisierte Testmahlzeit und eine nichtinvasive, postprandiale 
Endothelfunktionsmessung. Blutentnahmen erfolgten nüchtern, nach 15, 30, 60, 120, 180, 
240, 360, und 480 Minuten. Gesamtcholesterin, LDL-Cholesterin, HDL-Cholesterin, 
Gesamttriglyceride, VLDL-Triglyceride, ApoB, Glukose, Insulin, HOMA-IR, QUICKI, 
HbA1c, Adipokine, biochemische Marker der endothelialen Dysfunkktion (VCAM-1,  
ICAM-1 und Endothelin-1) und CRP wurden im Nüchternblut bestimmt. Das nüchtern Non-
HDL-Cholesterin wurde über die Gleichung Gesamtcholesterin - HDL-Cholesterin berechnet. 
Die „Area Under the Curve“ (AUC) und die inkrementelle AUC (iAUC) wurden für die 
postprandialen Gesamttriglyceride, VLDL-Triglyceride, Chylomikronen-Triglyceride, sowie 
für Glukose und Insulin bestimmt.  
 
Im Vergleich zur Kontrolldiät, wurde das Non-HDL-Cholesterin (Walnuss vs. Kontrolle:        
-10 ± 3 vs. -3 ± 2 mg/dl; p = 0.025) und ApoB (-5.0 ± 1.3 vs. -0.2 ± 1.1 mg/dl; p = 0.009) 
durch die Walnussdiät signifikant reduziert. Diese Ergebnisse blieben nach der Adjustierung 
von Alter, Geschlecht, BMI und Diät-Sequenz signifikant. Das Gesamtcholesterin (p = 0.073) 
zeigte einen Trend zur Reduktion. Nüchtern Gesamttriglyceride, VLDL-Cholesterin,       
LDL-Cholesterin, HDL-Cholesterin, Glukose, Insulin, HOMA-IR, QUICKI und HbA1c 
zeigten keine signifikante Veränderung. Nüchtern Adipokine, CRP, biochemische Marker der 
endothelialen Dysfunktion, postprandiale Lipide und Glukosewerte (AUC und iAUC) sowie 
die Ergebnisse der Endothelfunktionsmessung veränderten sich ebenfalls nicht signifikant.       
 
Die vorliegende Studie zeigte, dass die achtwöchige Supplementierung von 43 g Walnüssen 
eine günstige Wirkung auf das Plasmalipidprofil hat, in dem sie das Non-HDL-Cholesterin 
und Apolipoprotein B senkt. Die kurzfristige Walnusskonsum hatte keinen Einfluss auf den 
Glukosestoffwechsel, den Blutspiegel von Adipokine und CRP, sowie die endotheliale 
Funktion, das Körpergewicht und den Bludruck. Die günstige Wirkung auf das 
Plasmalipidprofil könnte zum Teil die epidemiologische Beobachtung der Reduktion der 
Häufigkeit von kardiovaskulären Erkrankungen durch Walnusskonsum erklären.  
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